Novo Nordisk acquires Danish biotech company

With the acquisition of Copenhagen-based biotech company Embark Biotech and its lead candidate, Novo Nordisk once again adds new opportunities to the pharmaceutical company’s obesity pipeline.

by CHRISTOPHER DUE KARLSSON

Just a few weeks ago, Novo Nordisk announced the acquisition of Canadian biotech company Inversago Pharma, whose main product is being developed to treat obesity. And the pharmaceutical company has now done it again.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Several suitors lined up for Embark Biotech: "Novo Nordisk made the best offer"
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom

The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.

For subscribers

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

Medtech

Olympus appoints new chief medical officer

For subscribers

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.
For subscribers
Vaccine breakthrough behind mRNA shots wins Nobel Prize
The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.
For subscribers
WS Audiology hires new chief technology officer from car manufacturer
He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.
For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.
For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.
For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.
For subscribers

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Pharma & biotech

Fujifilm expands management with former Leo executive

The contract manufacturer has hired a chief people officer with immediate effect.

For subscribers

Pharma & biotech

Novo Nordisk enters billion-dollar partnership with Valo Health

The agreement initially includes an upfront payment totaling USD 60m to Valo.

For subscribers

Scott Thomas Smith, CFO of Ascendis Pharma. | Foto: Ascendis Pharma / Pr

Pharma & biotech

Sale of royalties marks new approach to funding for Ascendis

Ascendis has historically raised capital through share issues, but that way of business is coming to an end.

For subscribers

Pharma & biotech

Ascendis gets USD 150m in cash from selling synthetic royalty

Starting January 2025, Royalty Pharma will receive a share of the revenue from the sale of weekly growth hormone Skytrofa in the US.

For subscribers

Robert Langer has received several honorary awards in his career. Here, he is pictured in 2013, when then US President Barack Obama presented him with the National Medal of Technology and Innovation. | Foto: Charles Dharapak/AP/Ritzau Scanpix

Pharma & biotech

Robert Langer to open doors for young biotech company: "But ultimately people need to be convinced by the idea and the data"

With Robert Langer on board, Hervolution will have a huge network of professionals to benefit from, and the renowned scientist’s reputation will increase investor interest, according to the analysis.

For subscribers